Table of Content


Table of Contents 2
Tables 5
Charts 6
Stada Arzneimittel AG - Key Company Facts 7
Stada Arzneimittel AG - Company Description 8
Stada Arzneimittel AG - Top Executives 9
Stada Arzneimittel AG - Top Executives Biographies 10
Stada Arzneimittel AG - Head Office & Locations 11
Head Office - Country 11
Key Subsidiaries 12
Stada Arzneimittel AG - Products and Services 13
Products 13
Stada Arzneimittel AG - Historic Events 14
Stada Arzneimittel AG - Company’s Management Discussion 16
Stada Arzneimittel AG - Corporate Strategy 18
Stada Arzneimittel AG - Business Description 20
Consumer Healthcare Segment 20
Generics Segment 20
Specialty Medicines Segment 21
Stada Arzneimittel AG - ESG Spotlight 22
Environment 22
Social 22
Corporate Governance 23
Stada Arzneimittel AG - SWOT Analysis 24
Overview 24
Strengths 27
Weaknesses 30
Opportunities 32
Threats 35
Competing Players 38
Snapshot of Competing Players 39
Roche Holding AG 39
Key Company Facts 39
Company Description 39
Johnson & Johnson 41
Key Company Facts 41
Company Description 41
Novartis AG 43
Key Company Facts 43
Company Description 43
Pfizer Inc. 45
Key Company Facts 45
Company Description 45
Merck & Co., Inc. 47
Key Company Facts 47
Company Description 47
Stada Arzneimittel AG - In the News 49
10-Oct-2024- EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar 49
28-Aug-2024- STADA continues strong growth journey in the first half of 2024 51
26-Jul-2024- STADA receives European Commission approval to expand label and patient group for IgA Nephropathy orphan medicine 55
22-Jul-2024- STADA launches ustekinumab biosimilar in Europe 56
24-Jun-2024- STADA Health Report 2024: Satisfaction with healthcare systems continues to decline - while individuals are caring more for their health 58
21-May-2024- STADA reduces carbon emissions and increases its renewable energy supply on sustainability journey 61
14-Mar-2024- STADA continues with double-digit sales and profit growth in 2023 63
10-Jan-2024- STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara 66
12-Dec-2023- STADA further improves Sustainability ranking again: rates among top 6% of pharma players globally 66
10-Nov-2023- STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara 67
28-Sep-2023- STADA and Calliditas announce the filing for full marketing authorization for Kinpeygo? in the EU 68
19-Sep-2023- STADA Health Report 2023: A Lack of Prevention Is Eroding Europeans’ Health 68

30-Aug-2023- People with Parkinson’s experience variations in effects of oral medicines, but lack advice, international survey reveals 69
15-Jun-2023- STADA appoints Christos Gallis as Head of Eastern Europe 69
01-Jun-2023- STADA: FDA approves biologics facility to supply key medicine to patients in US 70
06-Mar-2023- STADA sustains strong momentum with double-digit sales and profit growth in 2022 71
02-Jan-2023- STADA appoints Boris D?bler as Chief Financial Officer 71
20-Dec-2022- STADA ranks among top 10% of pharma firms on sustainability 73
Stada Arzneimittel AG - Key Deals 74
10-May-2024 - Xbrane and STADA partner with Valorum Biologics to commercialize ranibizumab biosimilar candidate in the US 74
09-Jan-2024 - Zuellig Pharma becomes STADA Philippines’ exclusive distribution partner 76
22-Nov-2023 - STADA strikes partnership with CR Sanjiu in China to drive growth of its cough and cold portfolio 76
12-Jul-2023 - STADA further grows its European Consumer Healthcare portfolio by acquiring several additional brands from Sanofi 76
03-Apr-2023 - STADA and Xbrane launch ranibizumab to support patient access in Europe 77
11-Jan-2023 - Adalvo and STADA extend their strategic partnership 78
28-Nov-2022 - STADA starts work on >EUR50m facility to strengthen European medicines supply 78
18-Mar-2022 - Ignis Therapeutics and STADA partner for apomorphine subcutaneous injection in China 79
Appendix 80
Definitions 80
SWOT Analysis 80
PESTLE Analysis 80
Value Chain Analysis 80
ESG Spotlight 80
Research Methodology 81
Disclaimer 82
Contact Us 82



List of Figures

Charts
Figure 1: Stada Arzneimittel AG - SWOT Analysis
Figure 2: Competing Players - Roche Holding AG - Key Financials
Figure 3: Competing Players - Johnson & Johnson - Key Financials
Figure 4: Competing Players - Novartis AG - Key Financials
Figure 5: Competing Players - Pfizer Inc. - Key Financials
Figure 6: Competing Players - Merck & Co., Inc. - Key Financials

List of Tables

Tables
Table 1: Stada Arzneimittel AG - Company Facts 7
Table 2: Stada Arzneimittel AG - Top Executives 9
Table 3: Stada Arzneimittel AG - Top Executives Biographies 10
Table 4: Stada Arzneimittel AG - Subsidiaries 12
Table 5: Stada Arzneimittel AG - Products 13
Table 6: Stada Arzneimittel AG - Historic Events 14
Table 7: Stada Arzneimittel AG -Competing Players 38
Table 8: Competing Players - Roche Holding AG - Key Company Facts 39
Table 9: Competing Players - Roche Holding AG - Key Financials 40
Table 10: Competing Players - Johnson & Johnson - Key Company Facts 41
Table 11: Competing Players - Johnson & Johnson - Key Financials 42
Table 12: Competing Players - Novartis AG - Key Company Facts 43
Table 13: Competing Players - Novartis AG - Key Financials 44
Table 14: Competing Players - Pfizer Inc. - Key Company Facts 45
Table 15: Competing Players - Pfizer Inc. - Key Financials 46
Table 16: Competing Players - Merck & Co., Inc. - Key Company Facts 47
Table 17: Competing Players - Merck & Co., Inc. - Key Financials 48